Abbott Laboratories (NYSE:ABT) Upgraded at Leerink Partnrs

Abbott Laboratories (NYSE:ABT - Get Free Report) was upgraded by analysts at Leerink Partnrs to a "hold" rating in a report issued on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Abbott Laboratories' Q2 2025 earnings at $1.26 EPS, Q3 2025 earnings at $1.30 EPS, Q4 2025 earnings at $1.48 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $5.74 EPS, FY2027 earnings at $6.34 EPS, FY2028 earnings at $6.97 EPS and FY2029 earnings at $7.64 EPS.

Several other equities research analysts also recently weighed in on ABT. Raymond James raised their price objective on Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. Citigroup raised their target price on Abbott Laboratories from $135.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Jefferies Financial Group upped their price target on Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research report on Thursday, April 17th. Morgan Stanley lifted their price objective on Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 17th. Finally, Barclays raised their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and an average target price of $142.61.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $133.99 on Monday. The firm has a 50 day moving average of $131.70 and a 200-day moving average of $126.58. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $233.12 billion, a PE ratio of 17.51, a PEG ratio of 2.52 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. On average, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds have recently made changes to their positions in the business. Tallon Kerry Patrick purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $200,000. LaFleur & Godfrey LLC boosted its position in Abbott Laboratories by 23.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 82,443 shares of the healthcare product maker's stock worth $9,325,000 after purchasing an additional 15,692 shares during the period. Brighton Jones LLC increased its stake in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $29,120,000. Finally, Van ECK Associates Corp grew its stake in Abbott Laboratories by 3.5% in the 4th quarter. Van ECK Associates Corp now owns 28,683 shares of the healthcare product maker's stock valued at $3,244,000 after buying an additional 957 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.